Latest Prasugrel Stories
TOKYO and INDIANAPOLIS, Feb. 23 /PRNewswire-FirstCall/ -- Heart patients with acute coronary syndrome (ACS) undergoing an artery-opening procedure will soon have a new treatment option to help prevent heart attacks.
Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel SCOTTSDALE, Ariz., Feb.
-- Portola to Receive $75 Million Upfront Cash Payment, $500 Million in Potential Milestone Payments Plus Royalties on Future Sales -- SOUTH SAN FRANCISCO, Calif., Feb.
TOKYO and INDIANAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- The U.S.
TOKYO and INDIANAPOLIS, Dec. 31 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today confirmed that the U.S.
TOKYO and INDIANAPOLIS, Dec.
SOUTH SAN FRANCISCO, Calif., Dec.
Portola Pharmaceuticals, a biopharmaceutical company, has announced new clinical data that demonstrate PRT060128, the company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity in patients who do not respond to clopidogrel.
NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov.
TOKYO and INDIANAPOLIS, Oct.
- Large; stout; burly.